Parabilis Medicines, Inc.
Limited financial coverage for PBLS.
Not enough data to compute a meaningful composite — typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available stats still render below.
Range $40 – $40
Price Chart
About the company
Fog Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them.
- CEO
- Mathai Mammen
- IPO
- 2026
- Employees
- 145
- HQ
- Cambridge, MA, US
AI snapshot
Six angles, distilled from the data.
The stock is still in a post-IPO digestion phase, trading above its 200-day average and closer to the middle of its 52-week range than to either extreme. That keeps the longer-term trend constructive, but the setup still needs sustained follow-through to challenge the prior high near 34.47.
Wall Street tone is positive, with two fresh initiations both landing on the bullish side: Guggenheim at Buy and Evercore ISI at Outperform. The published target cluster is tight at 40, which sits well above the recent trading range and signals room for rerating if clinical progress stays on track.
No earnings history is available yet, so the next report is more about pipeline execution than a beat/miss pattern. Estimates point to a slightly deeper loss next year, with EPS seen at -1.9 versus -1.78 TTM, so shareholders should watch cash use and clinical milestones closely.
No notable insider buying or selling in recent quarters. With no reported transactions, the tape offers no signal on management conviction beyond the company’s public clinical and financing posture.
The business remains loss-making, with EPS at -1.78 TTM and no reported profitability margins yet. Cash burn is heavy: operating cash flow was -123.7 million in 2025, while cash and equivalents stood at 27.7 million, so funding runway and trial spend matter.
As a clinical-stage biotech, PBLS is valued on pipeline optionality rather than current earnings power. The market is pricing in a premium path, with the share price still below the 40 consensus target and well above the low end of its 52-week range.
- 52W High
- $34.47
- 52W Low
- $24.51
- 50D MA
- $28.93
- 200D MA
- $28.93
- Beta
- 0.00
- RSI (14)
- 60
- Avg Volume
- 909.81K
No earnings-call transcripts are available for PBLS yet.
- Free Float
- 92.7%
- Shares Outstanding
- 3.27M
- Float Shares
- 3.03M
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Held by 31 ETFs
Biggest fund positions in PBLS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 22, 26 | RA CAPITAL MANAGEMENT, L.P. | buy | 47,250 |
| Jul 21, 26 | RA CAPITAL MANAGEMENT, L.P. | buy | 37,723 |
| Jul 21, 26 | RA CAPITAL MANAGEMENT, L.P. | buy | 6,504 |
| Jul 21, 26 | RA CAPITAL MANAGEMENT, L.P. | buy | 21,696 |
| Jul 20, 26 | RA CAPITAL MANAGEMENT, L.P. | buy | 32,987 |
| Jul 20, 26 | RA CAPITAL MANAGEMENT, L.P. | buy | 98,433 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PBLS coverage
Recent articles, reports, and earnings notes.
Want a deeper read on PBLS?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Here Are Monday’s Best Wall Street Analyst Research Calls: Agnico Eagle Mines, Datadog, Delta Air Lines, Gilead Sciences, Okta, Pfizer, Regions Financial, T-Mobile, and More
247wallst.com · Jul 6
This Parabilis Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
benzinga.com · Jul 6
This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested
fool.com · Jun 27
Fresh Off IPO, A Director Buys $474,000 of Parabilis Medicines Stock. Is PBLS a Buy?
fool.com · Jun 20
Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
globenewswire.com · Jun 11
Parabilis Medicines Announces Pricing of Upsized Initial Public Offering
globenewswire.com · Jun 9
Parabilis Medicines aims to raise $633 million in upsized US IPO
reuters.com · Jun 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
Bullish or bearish?
Where do you stand on PBLS?
AI analysis · Last refreshed July 20, 2026 · Live quote · Not investment advice
